相关临床试验
746
88 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1900
进行中（未招募）
69
9.3%
Available
1
0.1%
已完成
414
55.5%
Enrolling By Invitation
5
0.7%
No Longer Available
2
0.3%
尚未招募
14
1.9%
招募中
93
12.5%
暂停
3
0.4%
终止
76
10.2%
Unknown
16
2.1%
撤回
53
7.1%
暂无批准数据
- A multi-institutional team discovered MWAC-3634, a small molecule that blocks Ebola virus entry by stabilizing the viral entry protein rather than destabilizing it. - Screened from roughly 4.73 billion molecules using DNA-encoded chemistry, the compound inhibited authentic Ebola virus with an IC50 of 0.65 nM. - In a lethal mouse model, 85.7% of orally treated mice survived versus 28.6% of controls, with 100% survival among injected mice. - MWAC-3634 showed 69% oral bioavailability, but researchers caution it remains experimental and has not been tested or approved for human use.
- A new Science study using NanoSeq sequencing found platinum chemotherapy left an average of 2,200 mutations per liver sample in children treated for hepatoblastoma, a burden typical of adult livers. - Mutation load rose with platinum exposure, with children receiving both cisplatin and carboplatin showing more mutations than those given cisplatin alone. - Liver cells carried far more mutations than blood cells despite systemic treatment, suggesting the liver processes or repairs platinum damage differently. - A separate Nature study of 544 patients identified chemotherapy-specific genomic signatures that appeared as early as 91 days after treatment began.
- After more than 15 years of research, Baylor College of Medicine and Houston Zoo published the first peer-reviewed evidence that an experimental mRNA vaccine may protect young Asian elephants from EEHV. - Two companion papers in the Journal of Virology describe the vaccine's development and the first clinical evidence that vaccinated elephants withstood natural EEHV1A infection without severe disease. - On June 18, 2024, Houston Zoo's Asian elephant Tess became the first elephant ever to receive the experimental EEHV mRNA vaccine. - Two vaccinated juvenile elephants at Cincinnati Zoo experienced natural EEHV1A infection, remained clinically healthy, required no medical intervention, and recovered without developing hemorrhagic disease.
- A 2025 study published in Science Advances reveals metformin lowers blood glucose partly through the brain's ventromedial hypothalamus, not just the liver and gut. - Researchers at Baylor College of Medicine identified the Rap1 protein in the VMH as essential for metformin's glucose-lowering action in mouse models of type 2 diabetes. - Tiny doses of metformin injected directly into the brain significantly reduced blood sugar, while the brain responded to much lower concentrations than peripheral tissues. - The findings open potential new avenues for developing diabetes therapies that selectively target neural pathways involved in whole-body glucose regulation.
- Tikva Allocell secured $8 million in Series A financing led by Kantharos Capital to advance its lead allogeneic CAR-T candidate TAVST01. - The funding will support IND-enabling activities and a planned year-end 2026 IND submission for TAVST01 targeting B7-H3-positive solid tumors. - TAVST01 is built on the ALLO SerpinB9 EBVST platform using EBV-specific T cells engineered to resist immune rejection and minimize graft-versus-host disease. - Subject to regulatory clearance, Tikva plans to initiate a Phase 1 trial in patients with advanced B7-H3-positive cancers at sites in Singapore and the United States.
- Researchers at Baylor College of Medicine and Texas Children's Duncan NRI developed Tractor-Mix, a computational tool that accounts for both ancestry and family relationships in genetic studies. - The method, published in Nature Genetics, addresses a longstanding challenge where existing GWAS tools struggle with mixed-ancestry individuals and related participants. - Tractor-Mix successfully identified a previously undetected genetic region associated with body mass index (BMI) that conventional approaches missed. - The tool enables more inclusive genetic research, advancing precision medicine that benefits patients of all genetic backgrounds.
- Researchers at Baylor College of Medicine have uncovered why the cerebellum is selectively vulnerable in spinocerebellar ataxia type 1 (SCA1) despite the disease-causing ATXN1 protein being expressed throughout the brain. - The study reveals that two forms of the partner protein Capicua — CIC-Long and CIC-Short — have distinct binding preferences for ATXN1 and ATXN1L, respectively, driving tissue-specific toxicity. - Regional differences in the relative abundance of these protein forms dictate which brain areas are most affected, with the cerebellum showing the highest CIC levels. - The findings suggest that directing therapies to specific protein forms, rather than targeting the entire protein network, may improve treatment for SCA1 and potentially other neurological conditions.
- Illumina has launched TruPath Genome, a whole-genome sequencing workflow that eliminates traditional library prep and delivers 16 genomes per day in about 10 minutes of hands-on time. - The platform fully phases up to 98% of genes and extends accurate variant calling into difficult-to-map 'dark regions' of the genome using on-flow-cell library preparation and DRAGEN algorithms. - Data presented at AGBT showed TruPath Genome resolving challenging loci including the SMN1/SMN2 region in spinal muscular atrophy and genes linked to inherited adrenal disorders. - Broad Clinical Labs is among the first adopters, while more than 30 early access customers including GeneDx, Rady Children's Hospital and Baylor College of Medicine piloted the technology over 16 months.
- Loss of one copy of the DNA Ligase I (LIG1) gene in TP53-mutant triple-negative breast cancers is robustly associated with platinum-based chemotherapy resistance. - Researchers identified that combining the PARP inhibitor olaparib with the ATR inhibitor ceralasertib was significantly more effective than either drug alone in LIG1-loss models. - The study, published in Molecular Cancer Therapeutics, demonstrated reduced tumor growth in animal models using this combination strategy. - LIG1 status may serve as a predictive biomarker to stratify TNBC patients for future clinical trials evaluating ATR/PARP inhibitor combinations.
- Researchers at Baylor College of Medicine and the Duncan NRI have identified a novel actin-mitochondria-glutamate (AMG) biological pathway that can cause seizures when disrupted. - The study demonstrates that epilepsy can result from specific combinations of two or more defective genes, not just single-gene mutations, explaining many previously undiagnosed cases. - In fruit fly models, drugs targeting mitochondrial fragmentation (Mdivi-1) and reactive oxygen species (NACA) significantly suppressed seizures, suggesting new therapeutic strategies. - The findings offer a framework for improved genetic diagnosis by identifying pairs of seizure-associated genes, potentially benefiting the roughly 50% of epilepsy patients currently without a genetic diagnosis.
